Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III

Top-Line Psoriasis Efficacy Bested Placebo; Safety Similar To Phase II

 
• By Mandy Jackson

Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.

Dart arrow hitting in the target center of dartboard using as background Target business, achieve and victory,success concept.
Oral TYK2 inhibitor deucravacitinib (BMS-986165) met both primary endpoints in its first Phase III psoriasis study

More from Dermatological

More from Therapy Areas